Phase 2 Head and Neck Cancer Trial, Recruiting NCT07398664 Sponsor: West China Hospital Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 2 Head and Neck Cancer Trial, Recruiting

NCT07398664
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 79 years old.
  • People who have been diagnosed with a head or neck cancer confirmed by laboratory testing — this includes cancers of the nasopharynx, mouth, throat, voice box, salivary glands, nasal cavity, sinuses, and similar areas.
  • People whose cancer has stopped responding to at least two previous standard treatments, including treatments with cetuximab and an immunotherapy drug.
  • People whose doctors estimate they are likely to live for at least 3 more months.
  • People who are reasonably active and able to care for themselves, based on a standard medical activity scale scored 0 to 2 (confirm with trial site).
  • People whose blood test results before treatment show a neutrophil count above 2000/mm³ and a platelet count above 100,000/mm³ (these are types of blood cells measured in routine tests).
  • People whose liver and kidney function tests before treatment fall within acceptable ranges: bilirubin below 1.5 mg/dL, liver enzymes (AST or ALT) no more than 1.5 times the normal upper limit, and kidney markers (creatinine below 1.5 mg/dL and clearance above 60 mL/min).
  • People who are willing to follow the trial schedule and visits, and who are able to give written consent to participate.

Who may not be able to join:

  • People whose doctors estimate they are likely to live for less than 3 months.
  • Women of childbearing age who have a positive pregnancy test.
  • People with other serious ongoing health conditions that could affect their safety or ability to take part in the trial (confirm with trial site).
  • People with active mental health conditions that would prevent them from understanding the study or signing a consent form.
  • People with serious blood clotting problems or an active infection that currently requires treatment through an intravenous drip.
  • People who have had a different type of cancer within the past 5 years — except for certain skin cancers or a very early-stage form of thyroid cancer that has already been treated with the aim of curing it.
  • People with serious heart rhythm problems or high blood pressure that is not controlled by treatment (blood pressure above 150/90 mmHg).
  • People who still have side effects from previous cancer treatments that have not improved to a mild or resolved level, with some exceptions such as hair loss or mild nerve-related symptoms (confirm with trial site).
  • People who test positive for HIV, or who have active hepatitis B or hepatitis C infections, based on specific blood test results (confirm with trial site).
  • People who the trial doctors consider unsuitable for any other reason that could affect their safety or ability to follow the trial plan.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 086-18982770417

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
West China Hospital
Registry
ClinicalTrials.gov
Start date
2 March 2026
Est. completion
15 June 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective Response Rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov